The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 286.00
Bid: 286.50
Ask: 291.00
Change: 22.50 (8.54%)
Spread: 4.50 (1.571%)
Open: 262.00
High: 295.00
Low: 262.00
Prev. Close: 263.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q4 and FY trading update

20 Jan 2017 07:00

RNS Number : 6689U
Synthomer PLC
20 January 2017
 

Official Entity Name: SYNTHOMER PLC

LEI: 213800EHT3TI1KPQQJ56

 

20 January, 2017

 

Synthomer plc

 

Q4 and FY trading update

 

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the year ended 31 December 2016.

 

Europe and North America

The positive trends experienced in our Europe and North America business during the first three quarters of the year continued through Q4 leading to an overall performance ahead of our original expectations. We saw better than expected results across all business segments and further benefits from the ongoing focus on efficiency, new product initiatives, a strengthened procurement function and investment in business development activities.

 

Asia and Rest of World

Asia and Rest of World also performed modestly ahead of our expectations in Q4 with the competitive dynamics in our Asian Nitrile business continuing to evolve following the introduction of additional industry capacity in the second half of the year. Full year 2016 volumes and margins for this business are now likely to be sequentially ahead of FY 2015.

 

Hexion PAC

The integration and trading performance of Hexion PAC continues to progress in line with our expectations. The underlying annual EBITDA and expected synergies remain unchanged from the guidance given to the market in March 2016.

 

Full Year 2016

Due to the combination of a stronger trading performance in Europe and a slower evolution of the Asian Nitrile dynamics during Q4, we now expect 2016 performance on an underlying constant currency basis to be ahead of the top end of current market expectations.(1)

 

In addition, the Group will also benefit from the translation effect related to the ongoing weakness of sterling. Average YTD FX rates were €1.22 and $1.35, and are expected to provide a translational benefit of approximately £12m for the full year.

 

In reported currency, taking into account both these factors, the Board now anticipates that FY 2016 PBT will be approximately £120m.

 

2017 outlook

Looking forward to 2017, we still expect to see resilient trading in Europe although the raw material and macroeconomic environments remain volatile. We also expect our Asian Nitrile business to be further impacted by the introduction of the additional industry capacity in 2016. This will be partially offset by a full year of Hexion PAC included in the Group's results.

 

The Group will provide further detail on the outlook for 2017 with its 2016 Full Year results on 6 March 2017.

 

1. FY 2016 Consensus: Constant Currency Profit before Tax between £92.0m - £103.9m with consensus at £98.3m (Compiled by Teneo Blue Rubicon)

 

-ENDS-

 

Enquiries:

Stephen Bennett, Chief Financial Officer +44 1279 775 250

Charles Armitstead, Teneo Blue Rubicon +44 203 603 5220

 

The Company will hold a conference call for investors and analysts at 0900 BST today.

Please dial +44 (0) 808 237 0030 entering conference ID: 61421287# to gain access to the call.

 

The Company considers this announcement to contain inside information

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFMGMMRLZGNZM
Date   Source Headline
19th Jul 20217:00 amRNSTrading Update
14th Jul 202111:02 amRNSDirector/PDMR Shareholding
9th Jul 20217:00 amRNSAppointment of Non-Executive Director
6th Jul 202112:37 pmRNSDirector/PDMR Shareholding
25th Jun 202110:01 amRNSFurther re Appointment of Group CEO
23rd Jun 20217:00 amRNSAppointment of Group Chief Executive Officer
18th May 20213:53 pmRNSDirector Declaration
12th May 20212:56 pmRNSDirector Declaration
6th May 20214:17 pmRNSDirector Declaration
6th May 20213:15 pmRNSDirector/PDMR Shareholding
29th Apr 20214:01 pmRNSResult of AGM
21st Apr 20217:00 amRNSQ1 Trading Update
31st Mar 20219:00 amRNSDirector/PDMR Shareholding
31st Mar 20219:00 amRNSDirector/PDMR Shareholding
30th Mar 202110:56 amRNSAnnual Financial Report
19th Mar 20212:38 pmRNSDirector/PDMR Shareholding
12th Mar 20213:17 pmRNSDirector/PDMR Shareholding
12th Mar 20213:16 pmRNSDirector/PDMR Shareholding
12th Mar 20213:14 pmRNSDirector/PDMR Shareholding
12th Mar 20213:14 pmRNSDirector/PDMR Shareholding
11th Mar 20219:43 amRNSHolding(s) in Company
4th Mar 202112:43 pmRNSPreliminary results – correction
4th Mar 20217:00 amRNSPreliminary Results year ended 31 December 2020
1st Mar 202112:58 pmRNSHolding(s) in Company
24th Feb 20217:00 amRNSStatement RE: Press Speculation
22nd Feb 20214:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20214:35 pmRNSPrice Monitoring Extension
19th Feb 20213:38 pmRNSHolding(s) in Company
14th Jan 20217:00 amRNSPre-Close Trading Update and Board Update
12th Jan 20219:36 amRNSHolding(s) in Company
6th Jan 20219:10 amRNSDirector Declaration
4th Jan 202110:09 amRNSDirector Declaration
23rd Dec 20204:54 pmRNSDirector/PDMR Shareholding
17th Dec 20207:00 amRNSAppointment of New Chair
18th Nov 20207:00 amRNSInvestor Seminar
17th Nov 20201:34 pmRNSDirector/PDMR Shareholding
16th Oct 202010:33 amRNSHolding(s) in Company
14th Oct 20207:00 amRNSQ3 Trading Update
7th Oct 20209:20 amRNSHolding(s) in Company
4th Sep 20203:15 pmRNSDirector Declaration
6th Aug 20207:00 amRNSInterim Results for six months ended 30 June 2020
27th Jul 202010:00 amRNSPost Stabilisation Notice
16th Jul 20207:00 amRNSAppointment of Non-Executive Director
8th Jul 20204:16 pmRNSHolding(s) in Company
8th Jul 20204:14 pmRNSHolding(s) in Company
19th Jun 20207:00 amRNSSynthomer announces the pricing of senior notes
16th Jun 202011:54 amRNSPre Stabilisation Notice
16th Jun 202010:11 amRNSQ2 trading update
11th May 20205:21 pmRNSHolding(s) in Company
11th May 20209:03 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.